• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

TSRI’s Benjamin Cravatt elected to National Academy of Medicine

Bioengineer by Bioengineer
October 16, 2017
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: The Scripps Research Institute

LA JOLLA, CA – Oct. 16, 2017 – Benjamin Cravatt, professor and co-chair of the Department of Molecular Medicine at The Scripps Research Institute (TSRI), has been elected as a member of the prestigious National Academy of Medicine.

Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

"Ben is a remarkable scientist whose discoveries have greatly expanded new opportunities for drug development," said TSRI President and CEO Peter Schultz. "This honor is well-deserved and reflects the importance of Ben's work and the esteem in which he is regarded in the scientific community."

Cravatt is also a member of the National Academy of Sciences, to which he was elected in 2014. This puts him in a select group of scientists who have been honored with election to two of the three branches of the National Academies.

A prominent and inventive chemical biologist, Cravatt's research focuses on the role proteins play in cellular processes and how that knowledge can be used to identify novel therapeutic targets for the treatment of human disease. He has played a prominent role in developing and applying activity-based proteomics methods, which use chemical probes for the global analysis of protein function and drug action in native biological systems. This work has enabled the exploration of molecular drug targets once thought unreachable.

Cravatt's election to the National Academy of Medicine now expands to 10, the number of TSRI members in the distinguished group. In addition, TSRI has 21 members of the National Academies of Sciences and Engineering.

Cravatt holds an undergraduate degree from Stanford University and is an alumnus of the TSRI graduate program (class of '96), where he earned a doctorate in Macromolecular and Cellular Structure and Chemistry. Previous honors include his 2016 election to the American Academy of Arts and Sciences, one of the country's oldest learned societies and independent policy research centers.

Cravatt is a co-founder of Vividion Therapeutics, Abide Therapeutics and ActivX Biosciences and currently serves as an associate editor of the Journal of the American Chemical Society.

He was among 70 newly elected members and 10 foreign associates announced by the National Academy of Medicine today.

New members are elected by current active members through a selective process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care and public health.

###

For the full list of new members, see the National Academy of Medicine press release.

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists — including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine — work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see http://www.scripps.edu.

Media Contact

Madeline McCurry-Schmidt
[email protected]
858-784-9254
@scrippsresearch

http://www.scripps.edu

Original Source

http://www.scripps.edu/news/press/2017/20171016Cravatt.html

Share12Tweet7Share2ShareShareShare1

Related Posts

Engineered Gut Bacteria Enhance Survival Rates in Colorectal Cancer Patients

Engineered Gut Bacteria Enhance Survival Rates in Colorectal Cancer Patients

September 22, 2025
blank

Unveiling Toxocara canis Excretory-Secretory Products’ Impact

September 22, 2025

Oxaloacetate Sensing Boosts Innate Flu Defense

September 22, 2025

Nasal Staph Affects Mice Mood by Hormone Breakdown

September 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    68 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    50 shares
    Share 20 Tweet 13
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Metabolic Markers Identified as Potential Predictors of Breast Cancer Risk in High-Risk Women

How PRMT5-Mediated ACSL4 Methylation Inhibits Ferroptosis in Renal Carcinoma

Dana-Farber Unveils Innovative Diagnostic Tool Transforming Acute Leukemia Detection

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.